{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:09:27Z","timestamp":1784041767142,"version":"3.55.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["NW21-062B"],"award-info":[{"award-number":["NW21-062B"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["536814295"],"award-info":[{"award-number":["536814295"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BA 5132\/2-1"],"award-info":[{"award-number":["BA 5132\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC2151"],"award-info":[{"award-number":["EXC2151"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["390873048"],"award-info":[{"award-number":["390873048"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ctrv.2026.103157","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T22:17:15Z","timestamp":1778969835000},"page":"103157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical efficacy and immunological aspects of neoadjuvant and perioperative therapy in resectable head and neck carcinoma"],"prefix":"10.1016","volume":"148","author":[{"given":"Tessa","family":"Hattenhauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekka","family":"Mispelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz-Georg","family":"Bauernfeind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Baumjohann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Br\u00e4gelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annkristin","family":"Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Brossart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10167","key":"10.1016\/j.ctrv.2026.103157_b0005","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103157_b0010","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103157_b0015","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ctrv.2026.103157_b0020","first-page":"1","article-title":"Introducing checkpoint inhibitors into the curative setting of head and neck cancers: lessons learned, future considerations. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology","volume":"42","author":"Nenclares","year":"2022","journal-title":"Annual Meeting"},{"key":"10.1016\/j.ctrv.2026.103157_b0025","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","author":"Uppaluri","year":"2025","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103157_b0030","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science (New York, NY)"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103157_b0035","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2026.103157_b0040","first-page":"e390614","article-title":"Neoadjuvant immunotherapy in melanoma: the paradigm shift. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology.","volume":"43","author":"Hieken","year":"2023","journal-title":"Annual Meeting"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103157_b0045","article-title":"Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma","volume":"2","author":"Knochelmann","year":"2021","journal-title":"Cell Rep Med"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103157_b0050","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002568","article-title":"Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial","volume":"9","author":"Ferris","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103157_b0055","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial","volume":"26","author":"Uppaluri","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103157_b0060","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","article-title":"Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma","volume":"28","author":"Wise-Draper","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2026.103157_b0065","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1200\/JCO.2021.39.15_suppl.6008","article-title":"Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC)","volume":"39","author":"Uppaluri","year":"2021","journal-title":"JCO"},{"issue":"15","key":"10.1016\/j.ctrv.2026.103157_b0070","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","article-title":"Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single-arm phase 2 clinical trial","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0075","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/s41467-024-46444-z","article-title":"Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial","volume":"15","author":"Di","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0080","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1038\/s41467-024-49121-3","article-title":"Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial","volume":"15","author":"Gong","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103157_b0085","article-title":"Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: randomized, two-arm, phase 2 trial","volume":"6","author":"Liu","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ctrv.2026.103157_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106918","article-title":"Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma","volume":"156","author":"Zhao","year":"2024","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0095","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1038\/s41467-025-59004-w","article-title":"Efficacy, safety and single-cell analysis of neoadjuvant immunochemotherapy in locally advanced oral squamous cell carcinoma: a phase II trial","volume":"16","author":"Xiang","year":"2025","journal-title":"Nat Commun"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103157_b0430","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/cncr.34930","article-title":"A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma","volume":"129","author":"Patel","year":"2023","journal-title":"Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103157_b0100","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1200\/JCO.2023.41.16_suppl.6018","article-title":"Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC)","volume":"41","author":"Ferris","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103157_b0105","article-title":"Distinct CD8(+) T cell dynamics associate with response to neoadjuvant cancer immunotherapies","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103157_b0110","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103157_b0115","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1158\/1078-0432.CCR-23-3249","article-title":"A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma","volume":"30","author":"Kim","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0120","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1038\/s41467-025-59865-1","article-title":"Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial","volume":"16","author":"Liu","year":"2025","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103157_b0125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010634","article-title":"Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors","volume":"13","author":"Jinushi","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103157_b0130","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1158\/2767-9764.CRC-23-0051","article-title":"Phase II window study of olaparib alone or with cisplatin or durvalumab in operable head and neck cancer","volume":"3","author":"Moutafi","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103157_b0135","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1200\/JCO.2024.42.16_suppl.6073","article-title":"Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): an open-label, single-arm, phase 2 study","volume":"42","author":"Wei","year":"2024","journal-title":"JCO"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103157_b0140","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/1078-0432.CCR-21-1816","article-title":"Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma","volume":"28","author":"Luginbuhl","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hed.27915","article-title":"Pembrolizumab plus cetuximab with neoadjuvant chemotherapy for head and neck squamous cell carcinoma","volume":"47","author":"Yao","year":"2025","journal-title":"Head Neck"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103157_b0150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jamaoto.2025.4573","article-title":"Pathologic response and survival after neoadjuvant immunotherapy for resectable mucosal HNSCC: a systematic review and meta-analysis","volume":"152","author":"Mastrolonardo","year":"2026","journal-title":"JAMA Otolaryngol \u2013 Head Neck Surgery"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0155","article-title":"Epitope spreading and the efficacy of immune checkpoint inhibition in cancer","volume":"4","author":"Liu","year":"2021","journal-title":"Int J Oncology Res"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103157_b0160","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1158\/1078-0432.CCR-20-0305","article-title":"The role of antigen spreading in the efficacy of immunotherapies","volume":"26","author":"Brossart","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103157_b0165","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.4049\/jimmunol.1700643","article-title":"PD-1 blockade promotes epitope spreading in anticancer CD8(+) T cell responses by preventing fratricidal death of subdominant clones to relieve immunodomination","volume":"199","author":"Memarnejadian","year":"2017","journal-title":"J Immunol (Baltimore, Md 1950)"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103157_b0170","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s00262-012-1307-4","article-title":"Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo","volume":"61","author":"Jackaman","year":"2012","journal-title":"Cancer Immunol, Immunother CII"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0175","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008026","article-title":"Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103157_b0180","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124507","article-title":"Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy","volume":"3","author":"Fransen","year":"2018","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103157_b0185","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137365","article-title":"Importance of lymph node immune responses in MSI-H\/dMMR colorectal cancer","volume":"6","author":"Inamori","year":"2021","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103157_b0190","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","article-title":"Tertiary lymphoid structures and B cells: an intratumoral immunity cycle","volume":"56","author":"Fridman","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12943-024-01980-6","article-title":"Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0200","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2466308","article-title":"Spatial characterization of tertiary lymphoid structures as predictive biomarkers for immune checkpoint blockade in head and neck squamous cell carcinoma","volume":"14","author":"Ruiz-Torres","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2026.103157_b0205","article-title":"Retrospective study on the correlation between CXCL13, immune infiltration, and tertiary lymphoid structures in cutaneous squamous cell carcinoma","volume":"13","author":"Chen","year":"2025","journal-title":"PeerJ"},{"issue":"7791","key":"10.1016\/j.ctrv.2026.103157_b0210","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103157_b0215","article-title":"Tertiary lymphoid structures in cancer: maturation and induction","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2026.103157_b0220","article-title":"Association between tertiary lymphoid structures and clinical outcomes in cancer patients treated with immune checkpoint inhibitors: an updated meta-analysis","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0225","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1038\/s41467-021-23355-x","article-title":"B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma","volume":"12","author":"Ruffin","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103157_b0230","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-022-03310-5","article-title":"Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma","volume":"72","author":"Liu","year":"2023","journal-title":"Cancer Immunol, Immunother CII"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103157_b0235","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41590-024-01992-w","article-title":"Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma","volume":"25","author":"Shu","year":"2024","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103157_b0240","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002588","article-title":"T follicular helper cells: linking cancer immunotherapy and immune-related adverse events","volume":"9","author":"Baumjohann","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103157_b0245","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.trecan.2022.12.007","article-title":"T follicular helper cells in cancer","volume":"9","author":"Guti\u00e9rrez-Melo","year":"2023","journal-title":"Trends Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103157_b0250","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: a decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103157_b0255","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","article-title":"Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy","volume":"185","author":"Luoma","year":"2022","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103157_b0260","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-23-3296","article-title":"Tissue-resident T cells in clinical response and immune-related adverse events of immune checkpoint blockade","volume":"30","author":"Zhao","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103157_b0265","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science (New York, NY)"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103157_b0270","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ccell.2023.03.014","article-title":"Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer","volume":"41","author":"Sievers","year":"2023","journal-title":"Cancer Cell"},{"issue":"87","key":"10.1016\/j.ctrv.2026.103157_b0275","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adf4968","article-title":"Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer","volume":"8","author":"Oliveira","year":"2023","journal-title":"Sci Immunol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103157_b0280","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98811","article-title":"Frameshift events predict anti-PD-1\/L1 response in head and neck cancer","volume":"3","author":"Hanna","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ctrv.2026.103157_b0285","article-title":"Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model","volume":"13","author":"Guti\u00e9rrez Calder\u00f3n","year":"2021","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0290","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the friends of cancer research TMB harmonization project","volume":"8","author":"Merino","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103157_b0295","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrc.2018.11","article-title":"The molecular landscape of head and neck cancer","volume":"18","author":"Leemans","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103157_b0300","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/2159-8290.CD-20-1760","article-title":"Tumor immunity and immunotherapy for HPV-related cancers","volume":"11","author":"Shamseddine","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2026.103157_b0305","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.oraloncology.2019.03.012","article-title":"Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer","volume":"92","author":"Hong","year":"2019","journal-title":"Oral Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103157_b0310","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3892\/mmr.2017.6102","article-title":"Increased expression of PD\u2011L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity","volume":"15","author":"Liu","year":"2017","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0315","first-page":"279","article-title":"The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-na\u00efve tumors with immune checkpoint inhibitors","volume":"41","author":"Tosi","year":"2022","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103157_b0320","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hed.26036","article-title":"Impact of PD-L1 expression and human papillomavirus status in anti-PD1\/PDL1 immunotherapy for head and neck squamous cell carcinoma-systematic review and meta-analysis","volume":"42","author":"Patel","year":"2020","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0325","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s40136-021-00389-9","article-title":"Neoadjuvant immunotherapy strategies in HPV-related head-and-neck cancer","volume":"10","author":"Saito","year":"2022","journal-title":"Curr Otorhinolaryngol Rep"},{"issue":"6024","key":"10.1016\/j.ctrv.2026.103157_b0330","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science (New York, NY)"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0335","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev-immunol-101819-024752","article-title":"Beyond the barrier: unraveling the mechanisms of immunotherapy resistance","volume":"42","author":"Bell","year":"2024","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103157_b0340","doi-asserted-by":"crossref","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ctrv.2026.103157_b0345","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1200646","article-title":"Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy","volume":"13","author":"Czajka-Francuz","year":"2023","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103157_b0350","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121647","article-title":"Myeloid-derived suppressor cells: major figures that shape the immunosuppressive and angiogenic network in cancer","volume":"8","author":"Vetsika","year":"2019","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103157_b0355","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0360","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103157_b0365","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0370","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s42003-020-01441-y","article-title":"Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy","volume":"3","author":"Tu","year":"2020","journal-title":"Commun Biol"},{"issue":"7637","key":"10.1016\/j.ctrv.2026.103157_b0375","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0380","doi-asserted-by":"crossref","DOI":"10.4161\/onci.27588","article-title":"Implementing combinatorial immunotherapeutic regimens against cancer: the concept of immunological conditioning","volume":"3","author":"Wolf","year":"2014","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103157_b0385","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009352","article-title":"Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma","volume":"13","author":"Eigentler","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103157_b0390","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctrv.2026.103157_b0395","article-title":"Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives","volume":"16","author":"Shi","year":"2025","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103157_b0400","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1200\/JCO.24.00646","article-title":"Phase II trial of enfortumab vedotin in patients with previously treated advanced head and neck cancer","volume":"43","author":"Swiecicki","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103157_b0405","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.18632\/oncotarget.28299","article-title":"Nectin-4 is widely expressed in head and neck squamous cell carcinoma","volume":"13","author":"Sanders","year":"2022","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103157_b0410","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12964-024-01562-5","article-title":"The enhanced antitumor activity of bispecific antibody targeting PD-1\/PD-L1 signaling","volume":"22","author":"Li","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"10526","key":"10.1016\/j.ctrv.2026.103157_b0415","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0140-6736(25)01850-1","article-title":"Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial","volume":"407","author":"Bourhis","year":"2026","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ctrv.2026.103157_b0420","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-4813","article-title":"Neoadjuvant chemoimmunotherapy improves response rates in head and neck cancer","author":"Anderson","year":"2026","journal-title":"Clinical Cancer Research An Official Journal of the American Association for Cancer Research"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103157_b0425","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e18043","article-title":"EFFECT-neo: a phase 3 study of pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinoma","volume":"42","author":"Zhang","year":"2024","journal-title":"JCO"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722600071X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722600071X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:47:03Z","timestamp":1784040423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722600071X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":86,"alternative-id":["S030573722600071X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103157","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy and immunological aspects of neoadjuvant and perioperative therapy in resectable head and neck carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103157"}}